

## *Cancer Registry Report*

The Cancer Data Management System/Cancer Registry collects data on all types of cancer diagnosed or treated in an institution and is one of the four major components of an approved cancer program. From the reference or starting date of January 1, 1990, through December 31, 2005, GBMC's Cancer Registry has abstracted into its database the demographic, diagnostic, staging, treatment, and follow-up information on 30,557 cancer cases. To ensure accurate survival statistics, the Registry is required to follow these patients annually. GBMC's follow-up rate is 97%.

All data are reported quarterly to the Maryland Cancer Registry (MCR), which is part of the Maryland Department of Health and Mental Hygiene, and annually to the National Cancer Database (NCDB), the data management system for hospitals and programs approved by the Commission on Cancer. Co-sponsored by the American Cancer Society and the American College of Surgeons, the NCDB uses submitted data for comparative studies that evaluate oncology care and provides a Benchmark Summary of Cancer Care and Survival in the United States. The Cancer Committee at the Greater Baltimore Medical Center authorized our facility's 2004 data submission to the NCDB, which included site and stage data, to be posted to the American Cancer Society's web site ([www.cancer.org](http://www.cancer.org)). This Facility Information Profile System (FIPS) allows patients to view the types of cancers diagnosed and treated at a particular facility and can help patients make more educated decisions about their cancer care.

The MCR uses data to evaluate incidence rates for the entire state, and compares data by region and county; they also participate in national studies. In addition to required reporting, the Cancer Registry at GBMC provides data for physician studies and educational conferences. The Maryland Cancer Registry, the National Cancer Database and the Greater Baltimore Medical Center support web sites.

One part-time and 3 full-time Certified Tumor Registrars and a part-time follow-up clerk staff the Cancer Registry at GBMC. For additional information, call 443-849-8063.

### **Analysis**

The Cancer Registry accessioned 1,968 cases during calendar year 2005. Of these, 1,866 were analytic cases—those patients who were initially diagnosed at GBMC and/or received all or part of their first course of treatment at GBMC. The 102 non-analytic cases were initially diagnosed and treated at other facilities before referral to GBMC for additional treatment for recurrent disease or were initially diagnosed or treated at GBMC prior to January 1, 1990. Many of these non-analytic patients chose to be treated in one of the many clinical trials available at GBMC.

In 2005, the mean age at diagnosis for males at GBMC was 65.67; for females, it was 59.4.

The racial distribution of 1,968 cases includes 83.2% Caucasian, 15.8% African-American and 1% Asian. While 54.7% of patients diagnosed or treated at GBMC live in Baltimore County and 19.3% live in Baltimore City, patients come from 20 other Maryland counties, Pennsylvania, Delaware, and other states for treatment.

### **Site Distribution**

Breast cancer continues to be the most frequently diagnosed and/or treated cancer at GBMC, with 577 analytic cases. The second most commonly treated cancer at GBMC is prostate cancer with 179 analytics, followed by colon/rectum (160 analytics), lung (159 analytics), and thyroid (77 analytics). (See Tables 1 and 2) The American Cancer Society's Surveillance Research estimated that 25,450 new cancer cases would be diagnosed in Maryland in 2005. That same year, GBMC diagnosed and/or treated an increased number of cancers of the kidney (43 compared to 32 in 2004); oral cavity (31 compared to 21 in 2004); and pharynx (41 compared to 31 in 2004).

### **Staging**

To help the physician evaluate the patient's disease at diagnosis, estimate prognosis, guide treatment, evaluate therapy and access the results of early cancer detection, the American Joint Committee on Cancer (AJCC) has established a TNM Staging Classification based on the premise that cancers of similar sites and histologies share similar patterns of growth and extension. In the TNM staging system, T relates to extent of the primary tumor, N relates to lymph node involvement and M indicates the presence of distant metastases. The combination of the TNM gives a stage group classification of Stage 0, 1, 2, 3, 4, or unstageable. Cancers may be unstageable because no AJCC staging classification exists for the site. For example, leukemias, unknown primaries, and primary brain tumors cannot be staged using the AJCC criteria. Also patients may be unstageable because they choose to have no treatment or further testing

needed to determine the appropriate stage. At diagnosis, 13.7% of GBMC's 1,866 analytic cases were Stage 0 (in situ), the earliest stage tumors. In general, the survival rates for in-situ cancers are higher than for those of invasive cancers. Of the invasive cancers, 29.2 % were Stage 1; 23.4% were Stage 2; 12.7% were Stage 3; 11.7% were Stage 4; and 9.3% had no AJCC stage for the site or were unstageable (See Table 3).

Table 1

<b>GBMC Site Distribution</b>					
All Cases 2005					
Primary Site	Total Cases	Analytic	Non-Analytic	Male	Female
<b>GENITOURINARY</b>	311	292	19	279	32
Prostate	189	179	10	189	0
Renal	46	43	3	27	19
Bladder	55	49	6	43	12
Other GU	21	21	0	20	1
<b>BREAST</b>	601	577	24	4	597
<b>GASTROINTESTINAL</b>	245	237	8	129	116
Esophagus	7	6	1	5	2
Stomach	20	19	1	11	9
Colon/Rectum	164	160	4	82	82
Anal	12	12	0	5	7
Pancreas	25	24	1	14	11
Other GI	17	16	1	12	5
<b>GYNECOLOGIC</b>	197	190	7	0	197
Cervix Uteri	76	74	2	0	76
Corpus Uteri	66	62	4	0	66
Ovary	29	28	1	0	29
Other Gyn	26	26	0	0	26
<b>HEAD AND NECK</b>	200	192	8	102	98
Oral Cavity	32	31	1	17	15
Pharynx	42	41	1	35	7
Salivary Gland	10	10	0	7	3
Larynx	22	22	0	17	5
Thyroid	83	77	6	20	63
Other Head & Neck	11	11	0	6	5
<b>LUNG</b>	167	159	8	83	84
<b>LYMPH NODES</b>	62	57	5	31	31
<b>BONE MARROW</b>	49	45	4	22	27
<b>SKIN*</b>	57	43	14	29	28
<b>SOFT TISSUE SARCOMA</b>	9	8	1	6	3
<b>CNS</b>	27	27	0	14	13
<b>OTHER</b>	15	12	3	7	8
<b>UNKNOWN PRIMARY</b>	28	27	1	13	15
<b>ALL SITES TOTAL</b>	1,968	1,866	102	719	1,249
*Skin-Excludes basal/squamous skin cancers					
Source: GBMC Cancer Registry Database					

Table 2




Table 3

